Liraglutide Reduces Visceral and Intrahepatic Fat Without Significant Loss of Muscle Mass in Obese Patients With Type 2 Diabetes: A Prospective Case Series

BACKGROUND: Glucagon-like peptide-1 receptor agonists have been reported to reduce body fat as well as improving glycemic control in obese patients with type 2 diabetes. However, the maximum dose of liraglutide is limited to 0.9 mg in Japan, while the international dose is 1.8 mg; and the effect of...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Satoshi, Nagai, Yoshio, Sada, Yukiyoshi, Fukuda, Hisashi, Nakamura, Yuta, Matsuba, Ren, Nakagawa, Tomoko, Kato, Hiroyuki, Tanaka, Yasushi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2019
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396779/
https://www.ncbi.nlm.nih.gov/pubmed/30834046
http://dx.doi.org/10.14740/jocmr3647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6396779/
https://www.ncbi.nlm.nih.gov/pubmed/30834046
http://dx.doi.org/10.14740/jocmr3647

Ejemplares similares